Top Manufacturers Report of Global Lung Cancer Therapeutics : Forecast, Global Research 2018-2019
Press Release – 17
Jan 2019
Research
and Development News
--
.
.
Latest
Update
"Lung Cancer Therapeutics: Global Markets"
with Industries Survey | Global Current Growth and Future.
'
'
The global lung cancer therapeutic market was
valued at REDACTED in 2017 and expected to reach REDACTED by 2023,
increasing at a compound annual growth rate (CAGR) of REDACTED
between 2018 and 2023. Grant of fast-track designation to advance
therapies by the U.S. FDA, European Medicines Agency, CFDA (China)
and MHLW (Japan) is expected to significantly contribute to the
overall growth of the lungcancer therapeutics market. The global rise
in lung cancer incidence, improving survival rates, risingtobacco use
and environmental pollution, along with an increase in the
prescription volume of brandedtherapies in countries such as China,
are the major market drivers.
'
'
The lung
cancer therapeutic market is expected to grow significantly during
the forecast period, mainly due to an increase in the number of new
lung cancer cases. Lung cancer incidence in non-smoking group is
steadily increasing, mainly due to an increased exposure to
carcinogens such as radon, asbestos and exposure to radioactive
elements. This increase in non-smoking lung cancer cases is expected
to have a positive impact on the overall lung cancer therapeutic
market during the study period.
“Scope of Report”
This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
“Scope of Report”
This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
– For
Other Requirement and Enquiry_
https://www.researchmoz.us/enquiry.php?type=E&repid=1934417
'
'
Detailed
lung cancer therapeutic market analyses are presented for five
regions: North America, Europe, Asia-Pacific, the Middle East and
Africa, and South America.
Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.
“Reasons for Doing This Study”
There have been significant developments in understanding complex molecular and cellular mechanisms involved in lung cancer. As the incidence of lung cancer is increasing in regions such as Asia-Pacific and Europe, government agencies and research firms have shifted their focus on developing new treatment options to improve the lifespan of terminally ill patients. Increased use of targeted therapies and immunotherapies are proving to be beneficial to lung cancer patients. Several advanced therapies for lung cancer are likely to reach the market in the next five years.
Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.
“Reasons for Doing This Study”
There have been significant developments in understanding complex molecular and cellular mechanisms involved in lung cancer. As the incidence of lung cancer is increasing in regions such as Asia-Pacific and Europe, government agencies and research firms have shifted their focus on developing new treatment options to improve the lifespan of terminally ill patients. Increased use of targeted therapies and immunotherapies are proving to be beneficial to lung cancer patients. Several advanced therapies for lung cancer are likely to reach the market in the next five years.
Due to
increased healthcare expenditures on early screening and disease
detection, lung cancer therapy market dynamics are expected to change
during the forecast period. This study looks at different classes of
available drug types and their applications. This report also
identifies potential pipeline molecules, which could translate into
clinical practice during the forecast period.
This study highlights how the pharmaceutical sector is rapidly changing by forming new paradigms and employing marketing strategies that increase market share. The research provides information on leading market competitors, their market share, partnerships, collaborations, and mergers and acquisitions between pharmaceutical companies."
"Report Scope:
This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Detailed lung cancer therapeutic market analyses are presented for five regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.
Report Includes:
- 34 data tables and 32 additional tables
- An in-depth overview of the global market for lung cancer therapeutics within the industry
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Identification of key market dynamics, trends, opportunities and factors influencing the global lung cancer drug technology
- Assessment of major regulatory pathways and hurdles faced by lung cancer therapeutic product manufacturers
- Information pertaining to lung cancer drug patent applications, expirations and the latest key technology developments, pipeline analysis, reimbursement scenarios, and unmet needs associated with the market
- Dossier of mergers and acquisitions, new product development, strategies, research and development activities of major market players
- Examination of competitive landscape for the lung cancer therapeutics market, and information pertaining to leading lung cancer market players, their marketed products, pipeline products and product patent expirations
- Detailed company profiles of major manufacturers of oncology products, including Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Novartis International AG and Pfizer Inc."
This study highlights how the pharmaceutical sector is rapidly changing by forming new paradigms and employing marketing strategies that increase market share. The research provides information on leading market competitors, their market share, partnerships, collaborations, and mergers and acquisitions between pharmaceutical companies."
"Report Scope:
This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Detailed lung cancer therapeutic market analyses are presented for five regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.
Report Includes:
- 34 data tables and 32 additional tables
- An in-depth overview of the global market for lung cancer therapeutics within the industry
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Identification of key market dynamics, trends, opportunities and factors influencing the global lung cancer drug technology
- Assessment of major regulatory pathways and hurdles faced by lung cancer therapeutic product manufacturers
- Information pertaining to lung cancer drug patent applications, expirations and the latest key technology developments, pipeline analysis, reimbursement scenarios, and unmet needs associated with the market
- Dossier of mergers and acquisitions, new product development, strategies, research and development activities of major market players
- Examination of competitive landscape for the lung cancer therapeutics market, and information pertaining to leading lung cancer market players, their marketed products, pipeline products and product patent expirations
- Detailed company profiles of major manufacturers of oncology products, including Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Novartis International AG and Pfizer Inc."
Continue.....
– More
Clear Details get Full Table of Contents_
https://www.researchmoz.us/lung-cancer-therapeutics-global-markets-report.html/toc
About
Researchmoz,
ResearchMoz
is the world’s fastest growing collection of market research
reports worldwide. Our database is composed of current market studies
from over 100 featured publishers worldwide. Our market research
databases integrate statistics with analysis from global, regional,
country and company perspectives. ResearchMoz’s service portfolio
also includes value-added services such as market research
customization, competitive landscaping, and in-depth surveys,
delivered by a team of experienced Research
Coordinators.
--Researchmoz Global Pvt. Ltd.--
--Researchmoz Global Pvt. Ltd.--
Mr.
Nachiket G.
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074www.researchmoz.us
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074www.researchmoz.us
Comments
Post a Comment